ALG
Therapy and Standardization Workshop

Bad Soden (Ts)
April, 23rd—25th, 1972
Contents

Session 1
Activity: In-Vivo and In-Vitro Tests

H. BALNER
Standardization of Anti-Human Lymphocyte Sera by In Vivo Testing

A. D. BARNES, R. J. HAWKER, H. DUKES
The Use of Monkeys in Testing the Immunosuppressive Activity and Toxicity of Antihuman Lymphocyte Sera

D. E. KAYHOE, C. C. DARROW, R. C. SCOTT
The In Vivo Activity of Antilymphocyte Serum

E. WEINMANN, F. R. SEILER, G. GUTHOHRLEIN, H. BALNER
Comparative In-Vivo Testing of Isolated Fractions of/and Horse Anti-Human Lymphocyte Globulin in M. fascicularis and M. speciosa

J.-F. BACH
Antilymphocyte Serum Standardization by In Vitro Tests

D. C. EDWARDS, D. THOMAS, B. MOSEDALE, J. G. WOODROOFFE, H. ZOLA
The Immunosuppressive Potency of Antilymphocytic Sera and Globulins Predicted by the Use of the Immunofluorescence Test

R. JOHANNSEN, F. R. SEILER
The Micro-Complement Fixation Test as an Assay of the Immunosuppressive Activity of Anti-Human Lymphocyte Globulin (AHLG)

J. J. GOZZO, M. L. WOOD, R. POMPEI, A. P. MONACO
In Vitro Assay for Immunosuppressive Potency of Antilymphocyte Serum by the Technique of Passive Hemagglutination

J. P. REVILLARD
Inhibition of the Mixed Lymphocyte Reaction (MLC) and Immunosuppressive Activity of ALG

F. R. SEILER
Lymphocytotoxicity Test; Relation of Serological In Vitro Test Results to Prolongation of Skin Allograft Survival in M. Fascicularis

Session 2
Production and Purification

E. SIMPSON, R. M. BINNS, S. L. NEHLSEN, M. RUSZKIEVICZ
Sources of ALS

A. G. R. SHEIL
Relative Toxicity of ALG of Horse and Goat

A. D. BARNES, R. J. HAWKER, E. I. COWDALL, H. DUKES, J. FEJFAR, J. GRIFFIN
The Production of Anti-Human Thymocyte Antiserum in Various Species

A. D. BARNES, C. DICKERSON, R. J. HAWKER
The Production of Antilymphoblast Globulin for Clinical Use

E. M. LANCE
Some Comments on the Production and Purification of ALS with Special Reference to the Use of Lymphocyte Membranes

F. R. SEILER
Choice of Antigen for Raising AHLG: Summing-Up of Experiences During Several Years Development of a Clinical-Applicable Product

K. JAMES
The Preparation and Properties of Active Sub-Fractions from Anti-Lymphocytic Sera of Equine Origin

G. GUTHOHRLEIN, F. R. SEILER, K. HEIDE, G. REBER, H. G. SCHWICK
Large-Scale Production of Horse Anti-Human Lymphocyte Globulin (AHLG) for Clinical Use

C. G. GROTH, N. KASHIWAGI, G. E. MOORE, B. HUSBERG, Chr. BJORKEN, Ch. W. PUTNAM, Th. E. STARZL
Production of a Standardized Anti-Lymphocyte Globulin

A. J. PARCELLS, G. D. GRAY
The In Vitro Activities of Horse Antihuman Thymocyte Plasma
Session 3
Kidney-Transplantation: Clinical Reports

R. PICHLMAYR
Use of ALG in Clinical Kidney Transplantation; General Remarks

L. G. COLLSTE, H. COLLSTE, G. LUNDGREN, B. WERNER
Preliminary Experience with Routinely Applied AHLG in the Renal Transplant Program of Serafimerlasarettet Stockholm

The Use of Equine Antithymocyte Globulin in Renal Allograft Recipients

L. E. GELIN, B. STORM, J. AHLMEN
ALG-Treatment in Renal Homotransplantation

F. LARGIADER
Results of AHLG-Therapy in Kidney Allotransplantation

A. P. MONACO, R. SCHLESINGER, A. SAHYOUN
Experience with Equine Anti-Human Lymph Node Lymphocyte Serum in Renal Transplantation

J. A. MYBURGH
Antithymocyte Globulin in Cadaver Kidney Transplantation at the Johannesburg General Hospital

A. G. R. SHEIL, D. C. MEARNS, G. E. KELLY
Clinical Experience with Antilymphocyte Globulin Raised in Goats by Standardized Methods

R. L. SIMMONS, R. CONDIE, J. S. NAJARIAN
Anti-Lymphoblast Globulin for Renal Allograft Prolongation

Th. E. STARZL, D. CHARLES, W. PUTNAM
Clinical Experience with ALG

G. THIEL, F. BRUNNER, F. ENDERLIN, F. HARDER
Clinical Results with Intravenous Antilymphocyte Globulin (ALG) in Cadaver Kidney Transplantation

Session 4
Kidney-Transplantation: Panel Discussion

Session 5
Skin-Transplantation

A. G. DIETHELM, A. DIMICK, J. F. SHAW, H. BAKER, S. P. WILSON
Management of the Severely Burned Child Utilizing Skin Allografts Modified by Equine Antithymocyte Globulin

R. L. SIMMONS, A. W. MOBERG, R. CONDIE, J. S. NAJARIAN
Prolongation of Skin Allografts in Man Using Anti-Lymphoblast Globulin

H. BALNER
Proposal for a Collaborative Study to Compare the Effect of Antihuman Lymphocyte Sera on Skin Allograft Survival in Humans and Subhuman Primates

Session 6
Bone Marrow Transplantation

D. W. VAN BEKKUM
ALG in the Prevention of Acute Graft-Versus-Host-Reactions Following Allogeneic Bone Marrow Transplantation

L. SCHWARZENBERG, G. MATHE
Bone Marrow Transplantation after Antilymphocyte Globulin Conditioning Split Lymphocyte Chimerism

Session 7
Autoimmune Diseases

W. BRENDEL, J. SEIFERT, G. LOB, H. ANGSTWURM, E. FRICK, B. BRASS, J. MERTIN, H. BACKMUND
The Treatment of Autoimmune Diseases with ALG

B. PIROFSKY, J. C. RAMIREZ-MATEOS, E. J. BARDANA Jr., H. REID
Medical Uses of Antithymocyte Antisera Therapy
Session 8

Tumor Progression Risk

H. BALNER
Tumor Progression Under ALS; Some Recent Results 196

S. L. NEHLSEN
ATS-Mediated Immunosuppression and Tumor Risk 201

I. PENN, Th. E. STARZL
Immunosuppression and Neoplasia 204

R. E. WILSON
Malignant Tumor Experience at the Peter Bent Brigham Hospital 208

B. PIROFSKY, R. BEAULIEU, E. J. BARDANAJr.
Antithymocyte Antisera Therapy in the Presence of Human Lymphoid Neoplasia 212

M. BACH, A. P. MONACO
Incidence of Fungus and Nocardial Infections in Renal Transplant Patients Treated with Antilymphocyte Serum 217

Session 9

Immunological Effect of ALG in Humans. — Tolerance/Enhancement: with and/or without ALG

M. L. WOOD, J. J. GOZZO, A. P. MONACO
Studies on Tolerance/Enhancement Produced by Antilymphocyte Serum and Bone Marrow 220

E. M. LANCE
The Use of ALS to Abet the Development of Specific Non-Reactivity to Transplantation Antigens 223

J. A. MYBURGH, J. A. SMIT
Tolerance/Enhancement in the Baboon Liver Allograft Model 225

R. E. WILSON
Experimental Studies with Active and Passive Enhancement 227

Session 10a

ALG-Therapy and Standardization

B. PIROFSKY, R. BEAULIEU, A. AUGUST
Immunologic Effects of Antithymocyte Antisera in the Human 237

Session 10b

Summary Statements

E. M. LANCE
Summary Statement for Session (1): on In Vivo and In Vitro Testing of ALG 270

H. BALNER
Summary Statement for Session (2): Regarding Production and Purification 271

A. P. MONACO
Summary Statement of Session (3) and (4): Kidney Transplantation 272

D. W. VAN BEKKUM
Summary of Session (8): Tumor Progression Risk 274

P. B. MEDAWAR
Summary of Session (9): Tolerance and Enhancement in Relation to Use of ALG 275

Th. E. STARZL
Summary of the Bad Soden ALG-Workshop 276

H. G. SCHWICK
Final Remarks 278